MorphoSys and Incyte Announce Five-Year Results of L-MIND St

EQS-News: MorphoSys AG


/ Key word: Miscellaneous





MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL... | April 16, 2023

Related Keywords

United States , Orlando , Florida , Massachusetts , University Hospital , Boston , Planegg , Bayern , Germany , Canada , Delaware , American , Steven Stein , Tim Demuth , Johannes Duell , American Association For Cancer Research Annual Meeting , Nasdaq , Morphosys Us Inc , Exchange Commission , Xencor Inc , Practice Research Clinical Haematology , American Association For Cancer Research , Twitter , Drug Administration , Linkedin , Incyte Announce Five Year Results , Showed Prolonged , Durable Responses , American Association , Cancer Research Annual Meeting , Cancer Research , Annual Meeting , Medical Clinic , Chief Research , Development Officer , Chief Medical Officer , Diffuse Largeb Cell Lymphoma , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide , Prescribing Information , Patient Information , Important Safety , Morphosy Annual Report , Practice Research , Morphosys Ag Stock Exchange , News , Information , Press Release , Morphosys , Key , End , Incyte , Nnounce , Results , F , Study , Howed , Durable , Responses , N , Relapsed , Dr , Efractory Mor De0006632003 ,